Your browser is no longer supported. Please, upgrade your browser.
Settings
ACHL [NASD]
Achilles Therapeutics plc
Index- P/E- EPS (ttm)-0.61 Insider Own- Shs Outstand41.18M Perf Week-2.41%
Market Cap250.37M Forward P/E- EPS next Y-2.29 Insider Trans- Shs Float39.87M Perf Month-38.77%
Income-24.80M PEG- EPS next Q-0.49 Inst Own47.10% Short Float0.82% Perf Quarter-60.85%
Sales- P/S- EPS this Y-137.30% Inst Trans9.34% Short Ratio9.23 Perf Half Y-
Book/sh40.93 P/B0.15 EPS next Y42.60% ROA- Target Price- Perf Year-
Cash/sh4.32 P/C1.41 EPS next 5Y- ROE- 52W Range5.76 - 18.95 Perf YTD-63.26%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-68.60% Beta-
Dividend %- Quick Ratio11.30 Sales past 5Y- Gross Margin- 52W Low3.30% ATR0.48
Employees153 Current Ratio11.30 Sales Q/Q- Oper. Margin- RSI (14)21.29 Volatility5.33% 6.66%
OptionableNo Debt/Eq0.00 EPS Q/Q-450.30% Profit Margin- Rel Volume0.37 Prev Close6.08
ShortableYes LT Debt/Eq0.00 EarningsMay 11 BMO Payout- Avg Volume35.62K Price5.95
Recom1.80 SMA20-11.06% SMA50-39.37% SMA200-50.04% Volume5,555 Change-2.13%
Apr-26-21Initiated Piper Sandler Overweight $25
Apr-26-21Initiated Oppenheimer Outperform $23
Apr-26-21Initiated JP Morgan Underweight $11
Apr-26-21Initiated Chardan Capital Markets Buy $27
Apr-26-21Initiated BofA Securities Buy $20
Jul-26-21 03:00PM  
Jul-01-21 08:00AM  
04:40AM  
Jun-04-21 09:00AM  
May-11-21 07:00AM  
May-06-21 08:00AM  
May-05-21 08:30AM  
May-03-21 08:00AM  
Apr-10-21 08:30AM  
Apr-06-21 04:01PM  
Mar-31-21 02:01PM  
Mar-30-21 07:00PM  
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom.